MA55609A - Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih - Google Patents

Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih

Info

Publication number
MA55609A
MA55609A MA055609A MA55609A MA55609A MA 55609 A MA55609 A MA 55609A MA 055609 A MA055609 A MA 055609A MA 55609 A MA55609 A MA 55609A MA 55609 A MA55609 A MA 55609A
Authority
MA
Morocco
Prior art keywords
codv
tri
treatment
specific
binding proteins
Prior art date
Application number
MA055609A
Other languages
English (en)
Inventor
Mangaiarkarasi Asokan
Christian Beil
Jochen Beninga
Joerg Birkenfeld
Mark Connors
Richard A Koup
Young Do Kwon
Peter D Kwong
Qingbo Liu
Paolo Lusso
John R Mascola
Gary J Nabel
Amarendra Pegu
Ercole Rao
Ronnie Wei
Ling Xu
Zhi-Yong Yang
Original Assignee
Sanofi Sa
The United States Of America Represented By The Sec Dep Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, The United States Of America Represented By The Sec Dep Of Health And Human Services filed Critical Sanofi Sa
Publication of MA55609A publication Critical patent/MA55609A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA055609A 2019-04-09 2020-04-08 Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih MA55609A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962831415P 2019-04-09 2019-04-09
EP19306312 2019-10-08

Publications (1)

Publication Number Publication Date
MA55609A true MA55609A (fr) 2022-02-16

Family

ID=70471109

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055609A MA55609A (fr) 2019-04-09 2020-04-08 Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih

Country Status (15)

Country Link
EP (1) EP3953384A1 (fr)
JP (1) JP7676316B2 (fr)
KR (1) KR20210149796A (fr)
CN (1) CN114096561A (fr)
AU (1) AU2020273156A1 (fr)
BR (1) BR112021020346A2 (fr)
CA (1) CA3136147A1 (fr)
CO (1) CO2021014988A2 (fr)
IL (1) IL286932A (fr)
MA (1) MA55609A (fr)
MX (1) MX2021012384A (fr)
PH (1) PH12021500042A1 (fr)
SG (1) SG11202111011SA (fr)
TW (1) TW202104274A (fr)
WO (1) WO2020210386A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202330594A (zh) * 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CA3232365A1 (fr) * 2021-09-29 2023-04-06 Ronnie Rong Wei Polypeptides de liaison a l'antigene, complexes polypeptidiques de liaison a l'antigene et leurs methodes d'utilisation dans le vih
CN118251411A (zh) * 2021-09-29 2024-06-25 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
WO2026047100A1 (fr) * 2024-08-29 2026-03-05 Fundació Privada Institut De Recerca Sobre Immunopatologies-Caixa Irsicaixa Anticorps bispécifique pour l'activation des lymphocytes t en vue de l'élimination des cellules infectées par le vih

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2774636C (fr) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps neutralisants diriges contre le vih-1 et utilisation associee
WO2012154312A1 (fr) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps neutralisants anti-vih-1 et leur utilisation
BR112014010823B1 (pt) 2011-11-07 2021-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial
EP2788376B1 (fr) * 2011-12-08 2018-10-03 The United States of America, as represented by The Secretary, Department of Health and Human Services Anticorps neutralisants dirigés contre le vih-1 et leur utilisation
WO2013163427A1 (fr) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps pour traiter les infections par le vih-1
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
WO2017011414A1 (fr) * 2015-07-10 2017-01-19 Duke University Molécules bispécifiques comprenant un bras dirigé contre l'enveloppe du vih-1
RS62437B1 (sr) * 2015-10-25 2021-11-30 Sanofi Sa Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
CA3020633A1 (fr) 2016-04-13 2017-10-19 Sanofi Proteines de liaison trispecifiques et/ou trivalentes
EP3478324A1 (fr) * 2016-07-01 2019-05-08 GlaxoSmithKline Intellectual Property (No.2) Limited Conjugués anticorps-médicament et procédés thérapeutiques utilisant ceux-ci
RU2020130795A (ru) * 2018-02-21 2022-03-21 Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз Нейтрализующие антитела к env вич-1 и их применение
EP3953388A1 (fr) * 2019-04-09 2022-02-16 Sanofi Protéines de liaison trispécifiques, procédés et utilisations connexes
JP7518286B2 (ja) * 2020-08-25 2024-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法

Also Published As

Publication number Publication date
BR112021020346A2 (pt) 2021-12-07
CO2021014988A2 (es) 2022-01-17
AU2020273156A1 (en) 2021-12-02
SG11202111011SA (en) 2021-11-29
IL286932A (en) 2021-10-31
PH12021500042A1 (en) 2022-06-06
CN114096561A (zh) 2022-02-25
CA3136147A1 (fr) 2020-10-15
KR20210149796A (ko) 2021-12-09
EP3953384A1 (fr) 2022-02-16
MX2021012384A (es) 2022-02-21
TW202104274A (zh) 2021-02-01
JP7676316B2 (ja) 2025-05-14
JP2022526826A (ja) 2022-05-26
WO2020210386A1 (fr) 2020-10-15

Similar Documents

Publication Publication Date Title
MA55609A (fr) Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih
FR22C1063I2 (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
EP3746119A4 (fr) Procédés de traitement du cancer ou d'une infection à l'aide d'une combinaison d'un anticorps anti-pd -1, d'un anticorps anti-lag3 et d'un anticorps anti-tigit
EA201891028A1 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv
EP4025256A4 (fr) Compositions et procédés pour le traitement d'infections virales
EP3846846A4 (fr) Compositions et procédés pour le traitement d'infections virales
EP3283169A4 (fr) Utilisation d'anticorps anti-pacap et de leurs fragments de liaison à l'antigène pour le traitement, la prévention ou l'inhibition de la photophobie
EP3838517A4 (fr) Instrument pour robot d'assistance chirurgicale
EP3830183A4 (fr) Compositions à base de fucanes hautement purifiés et/ou modifiés pour le traitement d'adhérences fibreuses
EP3747449A4 (fr) Composition pharmaceutique comprenant des mitochondries isolées pour la prévention ou le traitement de la polyarthrite rhumatoïde
MA55720A (fr) Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
EP4121022A4 (fr) Compositions et méthodes pour le traitement et la prévention d'une infection à coronavirus
EP3313818A4 (fr) Procédés pour le traitement du sarcome de kaposi ou le lymphome induit par le kshv à l'aide de composés immunomodulateurs et utilisations de biomarqueurs
EP3902826A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de l'athérosclérose
EP3639829A4 (fr) Utilisation de l'isovalérylspiramycine i, ii et/ou iii dans la préparation d'un médicament pour le traitement et/ou la prévention d'une tumeur, et un médicament
EP3876928A4 (fr) Inhibiteurs de désacétylase d'histone utiles pour traiter ou prévenir une infection par le vih
EP4142728C0 (fr) 6'-méthoxycinchonan-9-ols pour le traitement d'infections à coronavirus
EP4021480A4 (fr) Peptides pour le traitement de troubles rénaux
MA54501A (fr) Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer
EP3903815A4 (fr) Préparation pharmaceutique pour le traitement de l'hépatite b, procédé de préparation s'y rapportant et utilisation associée
EA202092229A1 (ru) Мутеины cd4 и способы их применения
EP3802583A4 (fr) Procédés d'utilisation de cd24 pour la prévention et le traitement d'une rechute de la leucémie
EP3677267A4 (fr) Composition pharmaceutique pour le traitement ou la prévention de tumeurs, méthode et utilisation de celle-ci
EP3762014A4 (fr) Méthodes d'utilisation de cd24 soluble pour le traitement du syndrome d'immunodéficience acquise (vih/sida)
EP4251199A4 (fr) Méthodes et compositions pour le traitement d'une infection virale